Lincoln Pharma gets Gujarat FDA approval to manufacture Hydroxychloroquine and Hydroxychloroquine Sulfate Tablets to fight COVID19

Mr Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "We have all the necessary infrastructure at our state-of-the-art manufacturing facility at Khatraj, Ahmedabad and look to expedite the commercial production of the approved drugs at the earliest. Company is committed to fighting the COVID-19 pandemic and working closely with the governments and relevant stakeholders to ensure uninterrupted supply of medicines.

Company has also constituted a task force to handle the distribution of medicines and essential drugs with the primary objective of dealing with any kind of emergency or distress situation by COVID-19."

HCQ is a prescription based drug commonly recommended to Corona patients under treatment for the disease. India is the largest producer of HCQ and taking a lead in supplying this to the world in this time of crisis.

Lincoln Pharmaceuticals Ltd develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.

Read also: COVID-19 Testing Kits: Mylab Joins Hands With Syngene International